| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_116c851e729089df9a427027272fa290 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-24 |
| filingDate |
2014-04-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_de0a55a213e79bb0fb6b856ae873cf1b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d2b423974e9c53bb7746eab592784c09 |
| publicationDate |
2019-06-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
TW-201919702-A |
| titleOfInvention |
Anti-IL-4/anti-IL-13 bispecific antibody formulation |
| abstract |
The present invention provides a stable pharmaceutical antibody formulation (including a lyophilized formulation) comprising an anti-IL-4/anti-IL-13 bispecific antibody and a buffer system wherein the pH of the formulation is about pH 7. And wherein the formulation has a low salt concentration to facilitate reducing the ionic strength of the formulation. The formulation may further comprise a nonionic surfactant, a sugar and/or a nonionic stabilizer as desired. These formulations can be used to treat a variety of diseases. |
| priorityDate |
2013-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |